Vaccine News and Research

Latest Vaccine News and Research

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

Researchers identify primary player of the biochemical bugle call

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Embryonic stem cells hold great promise for biomedical science

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.

14 Jun 2012

Brazilian researchers say schistosomiasis vaccine could be available in 3 years

"Brazilian researchers say they have successfully tested a vaccine against schistosomiasis, a disease caused by parasitic worms that afflicts more than 200 million people worldwide," Agence France-Presse reports.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Clinical trials can benefit under-represented populations in developing countries

While conducting more clinical trials in developing countries can help under-represented populations benefit from new medical developments, trials in low-income settings face challenges such as complicated regulations, Trudie Lang of the Centre for Tropical Medicine at the University of Oxford and Sisira Siribaddana of the University of Rajarata and the Institute of Research & Development in Sri Lanka write in an essay published Tuesday in PLoS Medicine.

14 Jun 2012

IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine

Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

14 Jun 2012

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Today, the Sabin Vaccine Institute, in partnership with the George Washington University and the Children's National Medical Center, began vaccinating participants for a Phase 1 clinical trial of a novel human hookworm vaccine.

14 Jun 2012

Inovio to participate at Marcum Microcap Conference, BIO International Convention

Inovio Pharmaceuticals, Inc. announced today that Dr. Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.

14 Jun 2012

Cervical Cancer vaccine, increased awareness could help lower disease rate in Kenya

AllAfrica.com/Guardian examine efforts to prevent and treat cervical cancer among women in Kenya, where an estimated 3,400 women die of the disease each year and only five percent receive screening.

14 Jun 2012

MDA5 molecule plays a critical role in fighting viral infections

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

Children of GBS meningitis continue to have substantial long-term morbidity

Parents of infants who survive bacterial meningitis caused by group B Streptococcus might have to live with the effects of the disease on their children long after they're discharged from the hospital. A new study in the journal Pediatrics finds that even though mortality rates of children infected with GBS meningitis have decreased in the past 25 years, just under half of children who survive the disease will suffer impairment as a result of the disease.

13 Jun 2012

HLA B-27 protein appears to confer ability to suppress HIV viral replication

The rare ability of some individuals to control HIV infection with their immune system alone appears to depend - at least partially - on specific qualities of the immune system's killer T cells and not on how many of those cells are produced.

13 Jun 2012

Type 1 diabetes on the rise among young people in the U.S.

Jeffrey Brewer, president and CEO of JDRF, the leading global organization focused on type 1 diabetes (T1D) research, issued the following statement today in response to a new study showing an increase in T1D among young people in the United States.

13 Jun 2012

VaxInnate commences VAX161 Phase I trial in pandemic avian influenza

VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

13 Jun 2012

New data on individuals with natural ability to fight off AIDS

"Scientists on Sunday said they had found a key piece in the puzzle as to why a tiny minority of individuals infected with HIV have a natural ability to fight off the deadly AIDS virus," Agence France-Presse reports.

12 Jun 2012

Cellular source of cervical cancer found

A team of scientists from A*STAR's Institute of Medical Biology (IMB) and Genome Institute of Singapore (GIS) together with clinicians from Boston's Brigham and Women's Hospital (BWH) have identified a unique set of cells in the cervix that are the cause of human papillomaviruses (HPV) related cervical cancers. Significantly, the team also showed that these cells do not regenerate when excised.

12 Jun 2012

Chagas disease – ‘the AIDS of the Americas’

A recent editorial published in the Public Library of Science's Neglected Tropical Diseases called Chagas disease, a parasite which kills about 20,000 people a year, "the AIDS of the Americas." The disease can be transferred to a child from its mother or by blood transfusions. About 20 percent of those infected can develop life-threatening illness that includes enlarged hearts or intestines, and the drugs used today to treat the disease can take months to work.

12 Jun 2012

Opinion pieces published in advance of 'Child Survival Call to Action' event to take place in Washington

The following are summaries of several opinion pieces published in anticipation of the Child Survival Call to Action event to be held on June 14-15 in Washington, D.C. Convened by the Governments of United States, Ethiopia and India, and organized in close collaboration with UNICEF, the event will focus on ending preventable child death through the survival of newborns, children and mothers and will convene 700 prominent leaders from government, the private sector, faith-based organizations and civil society to kick off a long-term, focused effort to save children's lives.

12 Jun 2012